Publications by authors named "M Agulnik"

Claim this Profile
C
Chondrosarcoma: Clinical Behavior, Molecular Mechanisms, and Emerging Therapeutic Strategies.
Mark Agulnik, Breelyn A Wilky, Steven W Thorpe Facs, Lee M Zuckerman

Crit Rev Oncol Hematol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sarcoma: Cardiovascular and Oncologic Considerations: JACC: CardioOncology State-of-the-Art Review.
Daniel S Lefler, Elise F Nassif Haddad, Anju Nohria, Mark Agulnik, Jacquelyn Crane

JACC CardioOncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response to Letter to the Editor From Zhang et al: "Cabozantinib Plus Ipilimumab/Nivolumab in Patients with Previously Treated Advanced Differentiated Thyroid Cancer".
Bhavana Konda, Eric J Sherman, Erminia Massarelli, Jorge Nieva, Jameel Muzaffar, Mark Agulnik

J Clin Endocrinol Metab· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world survival outcomes and MDM2 prevalence in US patients with metastatic dedifferentiated liposarcoma.
Steven Robinson, Alyssa B Klein, Stephen A Stanhope, Kathryn Evans, Mark Agulnik

Future Oncol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A first-in-human, Phase 1/2a, open-label study of SQ3370, a first-in-class doxorubicin-based click chemistry therapeutic, in patients with advanced solid tumors.
S P Chawla, E Abella, S Wieland, T-H Nguyen, S Srinivasan, M Agulnik

medRxiv· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis